ClinicalTrials.gg
Not yet recruitingNCT07939451OptIMizeUpdated Nov 16, 2026

A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

A Phase 4 interventional study of Imetelstat (7.1 mg/kg) and Imetelstat (3.55 mg/kg) in MDS (Myelodysplastic Syndrome) and MDS, sponsored by Geron Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Geron Corporation · Phase 4, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic visit every four weeks. Participants won't be told which dose they receive, but their study doctors and the study sponsor will know.

The main goal is to learn whether the lower dose can be safer while still reducing transfusion needs.

Blood tests will be done often, especially early in treatment. If blood counts fall too much or other serious side effects occur, treatment may be delayed, lowered, or stopped. Participants in the lower-dose group who have no clear benefit after at least six treatment cycles may be allowed to move to the higher dose if they meet safety requirements. Study treatment can continue until the disease gets worse, side effects become too severe, patient chooses to stop, or the study ends. Study visits include blood tests, physical exams, vital signs, reviews of transfusions and side effects, and sometimes cardiac or bone marrow tests. Investigators will also collect extra blood samples to study imetelstat pharmacokinetic and how it affects blood cells and MDS-related genes.

Taking part is voluntary. Participants may leave the study at any time.

02

Conditions studied

  • MDS (Myelodysplastic Syndrome)
  • MDS

Keywords

  • imetelstat
  • dose optimization
03

In context

Lead sponsor

Geron Corporation is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman greater than or equal to (≥) 18 years of age
  • Diagnosis of MDS according to World Health Organization (WHO) 2016 classification confirmed by bone marrow aspirate and within 6 months prior to randomization that meets revised IPSS-R classification of very low, low, or intermediate risk disease
  • RBC transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to randomization; pre-transfusion should be ≤ 9.0 g/dL to count towards the 4 units total.
  • to, or ineligible for, erythropoiesis-stimulating agent (ESA) (EPO levels > 500 or per local guidelines); or Relapsed/refractory to, or ineligible for, erythroid maturation agent (EMA) (such as luspatercept) and has an endogenous serum EPO level >200 mU/mL at time of screening.
  • (ECOG) performance status 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Participant has known allergies, , or intolerance to imetelstat or its
  • Prior treatment with imetelstat
  • Participant has received an experimental or drug or used an invasive investigational medical device within 30 days of randomization
  • Has received greater than (>) 30 milligram per day (mg/day) prednisone or equivalent within 4 weeks prior to randomization, or growth factor treatment for a 7-day period or 7 half-lives of growth factor used prior to randomization, whichever is longer.
  • Has received ESA or EMA therapy within 4 weeks prior to randomization (8 weeks for long-acting ESAs) or any chemotherapy, immunomodulatory or therapy, within 4 weeks prior to randomization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Arm A: imetelstat 7.1 mg/kg

    Participants will receive imetelstat at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

    Drug: Imetelstat (7.1 mg/kg)

  • Experimental
    Arm B: imetelstat 3.55 mg/kg

    Participants will receive imetelstat at 3.55 mg/kg intravenous (IV) every 28days (±3 days), until disease progression or unacceptable toxicity, withdrawal of treatment or end of study.

    Drug: Imetelstat (3.55 mg/kg)

Interventions

  • DrugImetelstat (7.1 mg/kg)

    imetelstat will be given intravenously at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

  • DrugImetelstat (3.55 mg/kg)

    imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

06

What researchers measure

Primary outcomes

  1. Rate of ≥ 12-week Red Blood Cell Transfusion Independence (RBC TI) with concurrent mean Hgb rise of at least 1.5 g/dL

    Proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

    Time frame: Weeks 1-24

  2. Rate of Grade 3/4 thrombocytopenia by laboratory values

    Proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 thrombocytopenia events by laboratory values before subsequent anticancer therapy or dose escalation if any

    Time frame: Weeks 1-24

Secondary outcomes

  1. Rate of ≥ 12 weeks RBC TI

    Proportion of participants without any RBC transfusion during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

    Time frame: Weeks 1-24

  2. Rate of ≥ 12 weeks RBC TI with concurrent mean Hgb rise of at least 1.5 g/dL

    It is defined as the proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) at any time starting from randomization until subsequent anticancer therapy or dose escalation if any.

    Time frame: Up to End of Study (approximately 3.5 years)

  3. Rate of RBC TI ≥ 8 weeks, ≥12 weeks, ≥ 16 weeks, or ≥ 24 weeks

    Proportion of participants without any RBC transfusion during any consecutive 8, 12, 16, or 24 weeks (56, 84, 112, or 168 days) respectively at any time starting from randomization until subsequent anti-cancer therapy or dose escalation if any

    Time frame: Up to End of Study (approximately 3.5 years)

  4. Duration of RBC TI Response

    Duration of RBC TI defined as the first day of the longest RBC TI period to the date of the first RBC transfusion after the TI period started.

    Time frame: Up to End of Study (approximately 3.5 years)

  5. Time to RBC TI Response

    It is defined as the interval from randomization to the first day of corresponsive RBC TI response

    Time frame: Up to End of Study (approximately 3.5 years)

  6. Hgb peak and rise

    Hgb peak defined as the maximum Hgb value excluding values that were within 14 days after transfusion. Hgb rise defined as the difference between the Hgb peak and the pretreatment Hgb level

    Time frame: Up to End of Study (approximately 3.5 years)

  7. Rate of Hgb rise of at least 1.5 g/dL lasting ≥ 12 weeks

    Defined as the proportion of participants who had Hgb rise lasting at least 12 weeks during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

    Time frame: Up to End of Study (approximately 3.5 years)

  8. Rate of Hematologic Improvement Including Erythroid Response (HI-E) as Per International Working Group (IWG) Response Criteria 2018

    For low transfusion burden participants (who received 3 to 7 RBC units in the 16 weeks prior to trial entry): Clinically meaningful HI-E response per revised IWG 2018 is defined as 16-week RBC TI, i.e., participants without any RBC transfusion during any consecutive 16 weeks. For high transfusion burden participants (who received ≥ 8 RBC units in the 16 weeks prior to trial entry): * Major HI-E response per revised IWG 2018 is defined as 16-week RBC TI. * Minor HI-E response per revised IWG 2018 is defined as a reduction by at least 50% of RBC units over a 16-week period compared with the 16 weeks prior to trial entry.

    Time frame: Up to End of Study (approximately 3.5 years)

  9. Rate of disease progression, including AML progression

    Proportion of participants who had disease progression (or AML progression) per modified IWG 2006 criteria

    Time frame: Up to End of Study (approximately 3.5 years)

  10. Rate of Grade 3/4 neutropenia by laboratory values

    Defined as the proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 neutropenia events by laboratory values before subsequent anticancer therapy or dose escalation, if any

    Time frame: Weeks 1-24

  11. Treatment Emergent Adverse Events (TEAEs)

    Incidence, severity, and type of treatment emergent adverse events (TEAEs, with a specific focus on bleeding and infection events), and other clinical laboratory values (including liver function test \[LFT\] abnormalities)

    Time frame: Up to End of Study (approximately 3.5 years)

  12. Time to Resolution of Lab Events

    Time to resolution of Grade ≥ 3 neutrophil and platelet counts to baseline grade after end of dosing.

    Time frame: Up to End of Study (approximately 3.5 years)

  13. Assessment of Plasma concentrations of imetelstat

    Concentrations of imetelstat in Plasma

    Time frame: Cycles 1-6 (28 day cycles)

  14. Assessment of Cmax

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: Cycles 1-6 (28 day cycles)

  15. Assessment of AUC

    Area under the drug concentration-plasma time curve (AUC) from time zero to last measurable concentration

    Time frame: Cycles 1-6 (28 day cycles)

  16. Population PK/PD Model-Predicted Rates of Grade 3/4 Thrombocytopenia, Grade 3/4 Neutropenia, and Mean ≥1.5 g/dL Hemoglobin Increase Sustained for ≥12 Weeks

    Time frame: Cycles 1-6 (28 day cycles)

Other outcomes

  1. Time to acute myeloid leukemia (AML) progression among participants with documented AML progression

    Time frame: Up to End of Study (approximately 3.5 years)

  2. Assessment of biomarkers

    At baseline and change from baseline

    Time frame: Cycles 1-2 (28 day cycles)

  3. Assessment of Mutation status

    At baseline and change from baseline including at the time of suspected progression

    Time frame: Up to End of Study (approximately 3.5 years)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Jul 2030, 40 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
Mar 2027
Primary completionEst.
Jul 2030
CompletionEst.
Jan 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939451
Lead sponsor
Geron Corporation
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Mar 2027 (estimated)
Primary completion
Jul 2030 (estimated)
Completion
Jan 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Michelle Mudge-Riley, DO
Contact
mds4001-info@geron.com
+1 (650) 473-7793
Khaja Syed, PhD
Contact
mds4001-info@geron.com
+1 (650) 473-7793
Joseph E Eid, MD
study director · Geron Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion